Literature DB >> 180043

Evidence for altered synthesis of human chorionic gonadotropin in gestational trophoblastic tumors.

J L Vaitukaitis, E R Ebersole.   

Abstract

Tissue extracts of molar tissue or choriocarcinoma, blood, or urine of 21 women with gestational trophoblastic disease were analyzed for hCG and its subunits. The extracts or biologic fluids were initially chromatographed through a standardized Sephadex G-100 column. Each fraction was radioimmunoassayed in homologous hCG, hCGalpha, and hCGbeta assays. Extracts of four hydatidiform moles contained primarily hCG but no free alpha subunit of that hormone. One of the molar extracts contained a small amount of free hCGbeta not observed in the small amount of free hCGbeta not observed in the extracts of the other three moles. Plasma and urine samples from 18 women with localized or metastatic gestational trophoblastic disease contained hCG but no free alpha or beta subunits; the neoplasms of those patients readily responded to chemotherapy, and all patients have had no evidence of disease for at least one year. The major portion of immunologic hCG present in the biologic samples was indistinguishable from native hCG in its physical behavior on Sephadex G-100 chromatography. On the other hand, three women with widely metastatic tumors died in spite of extensive chemotherapy. Extracts of tumors from two of those patients contained hCG and free subunits of hCG. The urine and plasma of the third patient contained hCG and hCGalpha with the concentration of hCGalpha far exceeding that for hCG in urine. The results of these studies clearly show a disparity between the forms of hCG found in the normal placenta and pregnancy sera, as previously reported, and those found in the neoplastic trophoblast with varying degrees of anaplasia. The most striking finding was the absence of free circulating hCGalpha in the sera in patients with gestational trophoblastic disease which responded to chemotherapy, since free hCGalpha is readily detectable in the sera of normally pregnant women.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 180043     DOI: 10.1210/jcem-42-6-1048

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Predominance of gonadotropin alpha-subunit resulting from preferential loss of hCG beta production in an established cell line.

Authors:  R O Hussa; R A Pattillo
Journal:  In Vitro       Date:  1980-07

2.  Carboxyterminal peptide fragments of the beta subunit are urinary products of the metabolism of desialylated human choriogonadotropin.

Authors:  S Amr; C Rosa; S Birken; R Canfield; B Nisula
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

3.  Tumor-associated bacteria capable of producing a human choriogonadotropin-like substance.

Authors:  B T Backus; L F Affronti
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

4.  The free beta-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma.

Authors:  K Hotakainen; B Ljungberg; A Paju; T Rasmuson; H Alfthan; U-H Stenman
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

Review 5.  hCG: Biological Functions and Clinical Applications.

Authors:  Chinedu Nwabuobi; Sefa Arlier; Frederick Schatz; Ozlem Guzeloglu-Kayisli; Charles Joseph Lockwood; Umit Ali Kayisli
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

6.  StarD7 knockdown modulates ABCG2 expression, cell migration, proliferation, and differentiation of human choriocarcinoma JEG-3 cells.

Authors:  Jésica Flores-Martín; Viviana Rena; Sebastián Márquez; Graciela M Panzetta-Dutari; Susana Genti-Raimondi
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

7.  The Lipid Transfer Protein StarD7: Structure, Function, and Regulation.

Authors:  Jésica Flores-Martin; Viviana Rena; Sofía Angeletti; Graciela M Panzetta-Dutari; Susana Genti-Raimondi
Journal:  Int J Mol Sci       Date:  2013-03-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.